Coronavirus Vaccine Problems News StoriesExcerpts of Key Coronavirus Vaccine Problems News Stories in Major Media
Note: This comprehensive list of coronavirus vaccine problems news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
The COVID-19 vaccines' second dose can pack a heavy punch. But while most people experience flu-like symptoms and complain of a sore arm, musician and anti-lockdown activist Eric Clapton says his side effects included frozen limbs. Clapton wrote a note recently to Italian architect Robin Monotti Graziadei, who has shared numerous anti-lockdown posts on social media, where he called his experience receiving the AstraZeneca vaccine "disastrous." The former Cream guitarist said he got the vaccine in February. "I took the first jab of AZ and straight away had severe reactions which lasted ten days, I recovered eventually and was told it would be twelve weeks before the second one," Clapton wrote. "About six weeks later I was offered and took the second AZ shot," he continued. "Needless to say the reactions were disastrous, my hands and feet were either frozen, numb or burning, and pretty much useless for two weeks, I feared I would never play again, (I suffer with peripheral neuropathy and should never have gone near the needle.) But the propaganda said the vaccine was safe for everyone." The side effects of the AstraZeneca vaccine – which has not been approved yet for use in the U.S. – are described by the U.K. government as "mild to moderate in nature" and are expected to go away after a few days.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
The CDC announced Thursday that it will convene a meeting of its advisers on June 18th to discuss rare but higher-than-expected reports of heart inflammation following doses of the mRNA-based Pfizer and Moderna COVID-19 vaccines. So far, the CDC has identified 226 reports that might meet the agency's "working case definition" of myocarditis and pericarditis following the shots, the agency disclosed Thursday. The CDC first described the panel's session as an "emergency meeting," but later changed it to merely a "COVID-19 meeting." Previous times the advisors convened to discuss the pandemic – like their May 12th gathering to mull recommendations for Pfizer's COVID-19 vaccine in adolescents – were also described as "emergency meetings." The new details about myocarditis and pericarditis emerged first in presentations to a panel of independent advisers for the Food and Drug Administration, who are meeting Thursday to discuss how the regulator should approach emergency use authorization for using COVID-19 vaccines in younger children. The CDC previously disclosed that reports of heart inflammation were detected mostly in younger men and teenage boys following their second dose, and that there was a "higher number of observed than expected" cases in 16- to 24-year-olds. "Risk-benefit considerations â€¦ will need to account for this information," [said] Dr. Marion Gruber, director of the FDA's vaccine office."
Note: What this article fails to mention is that for every case reported there are very likely many that go unreported. Explore a much more in-depth article on this. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
All covid-19 vaccines currently in use in the US are available under emergency access only. None of the covid-19 vaccines in use are actually "approved." Through an emergency access mechanism known as Emergency Use Authorisation (EUA), the products being rolled out still technically remain "investigational." Factsheets distributed to vaccinees are clear: "There is no FDA approved vaccine to prevent covid-19." One key difference between EUA and approval (also called "licensure," and which for vaccines is known as a BLA (Biologics License Application)) was the expected length of follow-up of trial participants. Unlike its clear articulation of two months for an EUA, the FDA has not committed to a clear minimum for approval. Among the six "first in disease" vaccines approved by the FDA since 2006, pre-licensure pivotal trials were a median of 23 months in duration. Duration of protection is not the only question that longer, placebo controlled trials can address. They also address vaccine safety. The BMJ asked Moderna, Pfizer, and Janssen (Johnson and Johnson) what proportion of trial participants were now formally unblinded, and how many originally allocated to placebo have now received a vaccine. Pfizer declined to say, but Moderna announced that "as of April 13, all placebo participants have been offered the Moderna covid-19 vaccine and 98% of those have received the vaccine." In other words, the trial is unblinded, and the placebo group no longer exists.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Over the past two weeks, Seychelles – which has been dubbed "the most vaccinated country in the world" – has seen a spike in coronavirus cases, causing alarm. The archipelago in the Indian Ocean, with a population of about 98,000, has fully vaccinated more than 60% of its population, but it's also seen its number of active COVID-19 cases nearly double over the past month. The country has closed schools and canceled activities to attempt to curb the spread. Though Seychelles has been called the world's "most vaccinated country," not all vaccines are created equal. The country used two vaccines to inoculate its population – Sinopharm, a Chinese state-owned vaccine, and Covishield, a version of the AstraZeneca vaccine, both of which have not been proven to be as effective as the Pfizer-BioNTec and Moderna vaccines. Just last week, the WHO expressed "very low confidence" in data provided by Sinopharm around its risk of severe side effects. Recent clinical trial data found the vaccine was about 78.1% effective after two doses, but the Seychelles outbreak could suggest that the efficacy is less than that. Places like Seychelles also didn't see huge COVID surges earlier in the pandemic, and have lower levels of natural immunity in their communities. Chile is another example of a country with a high vaccination rate that now is seeing a spike in COVID-19 cases. Its number of new daily cases nearly doubled in April from the prior month, even though the country has vaccinated more than 45% of its population.
Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus vaccine from reliable major media sources.
No vaccine provides perfect protection, and so-called breakthrough infections after coronavirus vaccination are rare. Federal health officials have told fully vaccinated people they no longer need to wear masks or maintain social distance because they are protected, nor do they need to be tested or quarantine after an exposure, unless they develop symptoms. Now, the Centers for Disease Control and Prevention has stopped investigating breakthrough infections among fully vaccinated people unless they become so sick that they are hospitalized or die. Earlier this year, the agency was monitoring all cases. Through the end of April, when some 101 million Americans had been vaccinated, the C.D.C. had received 10,262 reports of breakthrough infections from 46 states and territories, a number that was very likely "a substantial undercount," according to a C.D.C. report. On May 1, the agency decided to investigate only the most severe breakthrough infection cases, while still collecting voluntary reports on breakthrough cases from state and local health departments. The agency will carry out vaccine effectiveness studies that include data on breakthrough cases, but only in limited populations, such as health care workers and essential workers, older adults, and residents at long-term care facilities. But even relatively mild cases of Covid-19 can lead to persistent long-term health problems, and it will be difficult to know the full scope without tracking mild infections as well.
Note: This is a convenient way to make it look like case numbers are dropping more than they actually are, which makes the vaccines look more effective than they really are. Learn more on how the CDC is manipulating case figures in this article. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus vaccine from reliable major media sources.
Covid-19 vaccines have created at least nine new billionaires after shares in companies producing the shots soared. Topping the list of new billionaires are Moderna CEO StÄ‚©phane Bancel and Ugur Sahin, the CEO of BioNTech, which has produced a vaccine with Pfizer. Both CEOs are now worth around $4 billion, according to an analysis by the People's Vaccine Alliance, a campaign group that includes Oxfam, UNAIDS, Global Justice Now and Amnesty International. Senior executives from China's CanSino Biologics and early investors in Moderna have also become billionaires on paper as shares skyrocketed. Moderna's share price has gained more than 700% since February 2020, while BioNTech has surged 600%. CanSino Biologics' stock is up about 440% over the same period. The company's single-dose Covid-19 vaccine was approved for use in China in February. Activists said the wealth generation highlighted the stark inequality that has resulted from the pandemic. The nine new billionaires are worth a combined $19.3 billion, enough to fully vaccinate some 780 million people in low-income countries. "These billionaires are the human face of the huge profits many pharmaceutical corporations are making from the monopoly they hold on these vaccines," Anne Marriott, Oxfam's health policy manager, said. "These vaccines were funded by public money and should be first and foremost a global public good, not a private profit opportunity," she added.
Note: You would hope that with all the suffering going on in our world, big Pharma wouldn't gouge and make huge profits on their vaccines. Sadly, this is far from the truth. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and the coronavirus vaccine from reliable major media sources.
For years, the Gates Foundation has been steered by an unusually small board of trustees, made up of Bill, his estranged wife, Melinda, and the billionaire investor Warren Buffett. The larger the foundation became, the less anyone seemed willing to ask tough questions about its secretive management structure or its penchant for giving money to lucrative pharmaceutical and credit card companies such as Mastercard, despite the fact that giving away billions to wealthy corporations set an unusual and troubling precedent in the philanthropic sector. Billionaires who make their fortunes through corporate practices that undercut workers and deepen inequality – like corporate tax avoidance, insufficient sick pay and the immoral gap in pay between executives and low-paid workers – are not the solution to problems they generate. Asking Bill Gates to fix inequality is like asking an arsonist to hose down your house after he just set it on fire. In April last year, the University of Oxford was reportedly considering offering a Covid-19 vaccine developed by its scientists on a nonexclusive basis. But then, Kaiser Health News reported, "Oxford – urged on by the Bill & Melinda Gates Foundation – reversed course. It signed an exclusive vaccine deal with AstraZeneca that gave the pharmaceutical giant sole rights and no guarantee of low prices." This dealmaking .. seemed to conflict with the Gates Foundation's stated mission to improve global access to medicines, but it's not surprising.
Note: Read more about the Gates Foundation's startling degree of media influence during the pandemic. For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption and the coronavirus vaccine from reliable major media sources.
A week ago, the Biden administration announced support for waiving intellectual property protection for Covid-19 vaccines. In response, Bio, a trade association representing biotechnology companies, issued a statement saying, "The United States has unfortunately chosen to set a dangerous precedent with these actions." Efforts to maintain intellectual property rights from life-saving drugs to vaccines have hindered the global response. The Biden administration surprised a lot of observers by coming out in favor of this ... temporary suspension of IP and patent enforcement on certain medications related to the Covid-19 pandemic. Right now, the way that wealthier countries – the U.S. and others – are confronting this crisis for the developing world is through voluntary agreements. There are really two ways to combat this crisis. There's a way to do it in a sense that maximizes profit for the healthcare companies, the pharmaceutical companies. And then there's the more collaborative, nonprofit approach. And early on, pharmaceutical companies were fighting this more collaborative approach. The pharmaceutical companies, in addition, have said they plan to increase prices once the pandemic quote-unquote ends. These companies are eagerly awaiting the opportunity to increase prices.
The pharmaceutical industry is distributing talking points, organizing opposition, and even collecting congressional signatures in an attempt to reverse President Joe Biden's support for worldwide access to generic Covid-19 vaccines. The behind-the-scenes moves ... come as the U.S. last week announced that it would support the World Trade Organization proposal, led by India and South Africa, to temporarily waive enforcement of intellectual property and patent rights on coronavirus vaccines. Without a radical expansion in vaccine manufacturing capacity, many developing countries will not achieve mass vaccination rates until 2023 or 2024. The waiver request, which was unexpectedly endorsed by Biden's administration on May 5, is designed to provide legal immunity for drug firms to copy the formulas of existing vaccines to supply low-cost vaccines to low-income countries. On Wednesday, Jared Michaud, a lobbyist with the Pharmaceutical Research and Manufacturers of America, a trade group that represents Pfizer, Johnson & Johnson, AstraZeneca, and other major drug firms, sent an email laying out the industry's role in coaxing lawmakers to push back against a waiver. One of the documents laid out potential national security concerns and suggested that lawmakers should argue the waiver could empower Russia and China. PhRMA ... spent over $24 million on federal lobbying last year and is one of the biggest corporate players in election spending.
Nearly 40% of US Marines are declining Covid-19 vaccinations, according to data provided to CNN on Friday by the service, the first branch to disclose service-wide numbers on acceptance and declination. As of Thursday, approximately 75,500 Marines have received vaccines, including fully vaccinated and partially vaccinated service men and women. About 48,000 Marines have chosen not to receive vaccines, for a declination rate of 38.9%. The declination rate at Camp Lejeune in North Carolina, one of the prominent Marine Corps bases, was far higher, at 57%, according to another set of data. Of 26,400 Marines who have been offered vaccinations, 15,100 have chosen not to receive them. The military cannot make the vaccines mandatory now because they have only emergency use authorizations from the Food and Drug Administration, meaning service members who are required to receive a series of other vaccinations have the option of declining shots to protect against Covid-19. Officials say most of the vaccine hesitancy stems from concerns about the speed at which the vaccines were developed and fears over long-term effects. The Defense Department has approximately 2.2 million service members operating around the globe.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
The pharmaceutical industry keeps turning up the dial on lobbying, setting massive new spending records in its intensive effort to influence Congress and the Biden administration. Yet this week, President Biden angered drugmakers when he said he supports the waiving of intellectual property protections for coronavirus vaccines. Drug and health product manufacturers, along with their national association, spent a combined $92 million to lobby the federal government from January through March. That puts the industry on track to break its spending record for the second year in a row. Not only that, but its first-quarter spending was more than double what was spent by the second-highest-spending industry, electronics companies. There are currently 1,270 registered lobbyists for pharmaceuticals and health products – more than two lobbyists for every member of Congress. Pfizer, maker of one of the three coronavirus vaccines approved for emergency use in the United States, was the biggest spender of any individual drug company. And last year, as it was developing its vaccine, the federal government agreed to pay the company $1.95 billion for the first 100 million doses it produced. The company reported it had $3.5 billion in revenue from sales of the vaccine so far this year. Pfizer was outflanked on lobbying spending only by the Pharmaceutical Research and Manufacturers of America – the national association that represents the interests of drugmakers.
The pharmaceutical industry is pouring resources into the growing political fight over generic coronavirus vaccines. Over 100 lobbyists have been mobilized to contact lawmakers and members of the Biden administration, urging them to oppose a proposed temporary waiver on intellectual property rights by the World Trade Organization that would allow generic vaccines to be produced globally. Pharmaceutical lobbyists working against the proposal include Mike McKay, a key fundraiser for House Democrats, now working on retainer for Pfizer, as well as several former staff members to the U.S. Office of Trade Representative, which oversees negotiations with the WTO. Several trade groups funded by pharmaceutical firms have also focused closely on defeating the generic proposal, new disclosures show. The U.S. Chamber of Commerce, the Business Roundtable, and the International Intellectual Property Alliance, which all receive drug company money, have dispatched dozens of lobbyists to oppose the initiative. The push has been followed by a number of influential voices taking the side of the drug lobby. Last week, Sen. Thom Tillis, R-N.C., released a letter demanding that the administration "oppose any and all efforts aimed at waiving intellectual property rights." Currently, only 1 percent of coronavirus vaccines are going to low-income countries, and projections show much of the world's population may not be vaccinated until 2023 or 2024.
Note: Has it ever been more clear that big Pharma places profits above health, even when it might cause huge numbers of people to die? For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and coronavirus vaccines from reliable major media sources.
In the coming months, Linda Thomas-Greenfield, President Joe Biden's ambassador to the United Nations, will hear from a growing chorus of developing nations about the foundering efforts to distribute the coronavirus vaccine globally. The nations, many of which have not even begun vaccinating their populations, are demanding that the U.S. support proposals to temporarily waive certain patent and intellectual property rights so that generic coronavirus vaccines can be produced. The proposals have been fiercely opposed by American drugmakers, including Pfizer. ASG ... represents Pfizer. Many leading figures in Biden's administration, including key White House advisers, State Department leaders, and health care officials have financial stake in or professional ties to vaccine manufacturers, which are now lobbying to prevent policies that would cut into future profits over the vaccine. ASG in particular has unusual amounts of sway in the Biden administration. State Department officials Victoria Nuland, Wendy Sherman, Uzra Zeya, and Molly Montgomery previously worked at ASG, as did Philip Gordon, Vice President Kamala Harris's national security adviser. The pharmaceutical industry, in a bid to shield an expected financial windfall, has pressed the Biden administration not only to oppose the waiver, but also to impose trade-related sanctions on countries that back [a] proposal or move to manufacture coronavirus vaccines without permission from patent holders.
Pfizer expects to sell $15 billion worth of Covid-19 vaccines in 2021. That would make it the second-highest revenue-generating drug anytime, anywhere, according to industry reports. The maker of the first Covid-19 vaccine to be approved for use in advanced markets has released its earning forecasts for 2021 today. Pfizer expects to earn between $59 billion and $61 billion - up from $42 billion it made in 2020. Sales of the vaccine are set to bring in about a fourth of Pfizer's total revenue this year. That would be nearly as much as its three best-selling products combined. The company is expecting profit margins for the vaccine to be between 25% and 30% which means profits from the vaccine could be around $4 billion. All of Pfizer's costs and profits from the vaccine are split evenly with BioNTech, the biotech company that helped develop the treatment. There are is only one drug in the world that sells more - Humira, a prescription medication for arthritis. Pfizer plans on selling 2 billion doses of the vaccine this year, but that demand should subside in coming years so the revenue of Covid-19 vaccine won't be stable, Pfizer's CEO Albert Bourla said on an call with analysts and investors. The company expects to continue profiting from it by selling booster doses, including ones required to shield against new variants of the virus, Bourla said. Further, Pfizer is pursuing more avenues to employ the mRNA technology underlying the vaccine, including a flu vaccine and other therapeutic applications.
Note: Read more in this revealing Reuters article. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines and Big Pharma profiteering from reliable major media sources.
AstraZeneca may have included "outdated information" in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusual public rift that could further erode confidence in the shot. In an extraordinary rebuke, just hours after AstraZeneca on Monday announced its vaccine worked well in the U.S. study, an independent panel that oversees the study scolded the company for cherry-picking data, according to a senior administration official. The panel wrote to AstraZeneca and U.S. health leaders that it was concerned the company chose to use data that was outdated and potentially misleading instead of the most recent and complete findings. The NIH's Dr. Anthony Fauci told ABC's "Good Morning America" that the incident "really is what you call an unforced error" and that he expects the discrepancy to be straightened out. But that nitty-gritty seldom is seen by the public, something now exposed by the extraordinary microscope being applied to development of the world's COVID-19 vaccines. The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then last week a scare about blood clots that had some countries temporarily pausing inoculations. Company executives refused repeated requests from reporters to provide a breakdown of the 141 COVID-19 cases it was using to make the case for the shot's effectiveness.
Germany, France, Spain, Italy, Ireland and the Netherlands have joined the growing list of countries that have suspended the use of the coronavirus vaccine developed by AstraZeneca and the University of Oxford over blood clot concerns. The Dutch government said Sunday that the Oxford-AstraZeneca vaccine would not be used until at least March 29, while Ireland said earlier in the day that it had temporarily suspended the shot as a precautionary step. On Monday, the German government also said it was suspending its use, with the vaccine regulator, the Paul Ehrlich Institute, calling for further investigations. The Italian medicines authority made a similar announcement on Monday afternoon and French President Emmanuel Macron also said the vaccine's use would be paused pending a verdict from the EU's regulator. Spain Health Minister Carolina Darias said Monday that the country will halt use of the shot for at least two weeks. Portugal and Slovenia also suspended the vaccine. Thailand has also halted its planned deployment of the vaccine. The move to pause its use by Dutch and Irish officials came shortly after Norway's medicines agency said it had been notified of three health workers being treated in hospital for bleeding, blood clots and a low count of blood platelets after receiving the Oxford-AstraZeneca vaccine. Norway has put its Oxford-AstraZeneca vaccine program on hold.
Note: Many countries have resumed using this vaccine after Europe's medicines regulator concluded it was "safe and effective". For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
The factory that Pfizer Inc. plans to use to boost production of its covid-19 vaccine for the massive U.S. inoculation effort was cited by federal inspectors last year for repeated quality-control violations. Food and Drug Administration inspectors visited the McPherson, Kansas, plant at the end of 2019 into January 2020, according to an inspection report. They found the drug giant released medications for sale after failing to thoroughly review quality issues that arose in routine testing, the report shows. Additionally, the report says inspectors found bacteria and mold in supposedly sterile areas, an issue seen in previous visits to the facility. And the plant failed to properly sample drug products to ensure they didn't have excessive levels of certain toxins, the inspectors wrote. The FDA sent Pfizer a warning letter, the agency's strongest rebuke, concerning the factory in 2017 after the agency detected issues similar to those it found in 2020. The FDA concluded that Pfizer had addressed the violations in June 2018, a month before it returned to the facility and found more problems. The company plans to supply the U.S. with 200 million doses of its two-shot vaccine regimen by the end of May. The FDA halted all inspections of drugmaking facilities at the beginning of the Covid-19 pandemic, though it has since resumed some domestic visits. Pfizer's plant in Kansas is also authorized to make the Covid-19 treatment remdesivir.
President Joe Biden's administration is being asked to punish Hungary, Colombia, Chile, and other countries for seeking to ramp up the production of Covid-19 vaccines and therapeutics without express permission from pharmaceutical companies. The sanctions are being urged by the drug industry, which has filed hundreds of pages of documents to the Office of the U.S. Trade Representative outlining the alleged threat posed by any effort to challenge "basic intellectual property protections" in the response to the coronavirus pandemic. The drug industry has sharply criticized any attempt to share vaccine patents or the technological knowledge needed to manufacture them, despite global need. The strident corporate opposition to any intellectual property flexibility has rankled public health advocates, many of whom note that much of the vaccine technology has been financed by the public sector. The Pfizer vaccine, noted Prabhala, was developed in partnership with the European firm BioNTech, which received $445 million from the German government to help accelerate vaccine development and manufacturing. The U.S. government provided about $1 billion for the research and testing by Moderna to create its coronavirus vaccine. Johnson & Johnson received over $1.45 billion in funding from the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services, for its recently approved Covid-19 vaccine.
A little more than a third of nursing home workers have been getting COVID-19 vaccines when the shots are first offered, U.S. health officials said Monday. The Centers for Disease Control and Prevention gave a national accounting of a problem that's been reported anecdotally – many nursing home workers are not getting the shots. The CDC looked at more than 11,000 nursing homes and skilled nursing facilities that had at least one vaccination clinic between the middle of December and the middle of January. The researchers found that while 78% of residents got at least one shot, only 37.5% of staff members did. Data previously showed that people who work in nursing homes and long-term care facilities get flu vaccines at lower rates than other health-care workers. Surveys suggest that long-term care workers are skeptical the shots work and don't think viruses spread easily from them to the people they care for. The CDC released a second report Monday that offered a larger national look at who has been getting the vaccine. The CDC study found that of the people who got at least one shot between mid-December and mid-January, 63% were women, and 55% were age 50 or older.
The goal of this project is to improve the quality of vaccination programs by improving the quality of physician adverse vaccine event detection and reporting to the national Vaccine Adverse Event Reporting System (VAERS). Restructuring at CDC and consequent delays in terms of decision making have made it challenging despite best efforts to move forward. Adverse events from drugs and vaccines are common, but underreported. Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported. Low reporting rates preclude or slow the identification of "problem" drugs and vaccines that endanger public health. New surveillance methods for drug and vaccine adverse effects are needed. Barriers to reporting include a lack of clinician awareness, uncertainty about when and what to report, as well as the burdens of reporting: reporting is not part of clinicians' usual workflow, takes time, and is duplicative. Unfortunately, there was never an opportunity to perform system performance assessments because the necessary CDC contacts were no longer available and the CDC consultants responsible for receiving data were no longer responsive to our multiple requests to proceed with testing and evaluation.
Note: The U.S. government here is admitting that less than 1% of vaccine injuries are reported. What does this say about the safety of vaccines in general? For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.